Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half
Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing IVT injection patient discomfort.
Read original at benzingaStocks · News reference
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 5:56 PM
- Checked
- Aug 6, 2026, 5:56 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Harrow Reports Statistically Significant Results Favoring IHEEZO In Intravitreal Injection Study
Read original at benzingaBTIG Reiterates Buy on Harrow, Maintains $63 Price Target
BTIG analyst Thomas Shrader reiterates Harrow (NASDAQ:HROW) with a Buy and maintains $63 price target.
Read original at benzingaOppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26 guidance. Other stocks also down in pre-market.
Read original at benzingaViatris shares are trading lower despite reporting better-than-expected Q2 financial results, possibly dragged down by wider GAAP net loss, near-term supply risks, and weakness in Emerging Markets.
Read original at benzinga8-K filing — Viatris Inc (VTRS)
Filed: 2026-08-06 AccNo: 0001792044-26-000037 Size: 874 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar